Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer (WARP)

November 16, 2026 updated by: University of Zurich

Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer (WARP)

This interventional prospective multicenter international study will include 54 patients with regionally metastatic (i.e. cN1 cM0) prostate cancer according to the NCCN criteria.

Patients will be treated with weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy. A simultaneous integrated boost (SIB) of involved lymph nodes will be performed. In the case of up to 2 dominant intraprostatic lesion (DIL) a SIB of the DIL can be performed (optional). Importantly, coverage of these DIL volumes must be compromised as needed to respect OAR constraints.

This study is classified as risk category A according to ClinO, Art. 61, as stereotactic radiotherapy (SBRT) for regionally metastatic prostate cancer has been extensively evaluated in prospective interventional trials and is considered an established therapeutic modality.

Weekly CT- or MR-guided online adaptive SBRT to the prostate and elective pelvic lymph nodes with 5 × 5 Gy is, however, not yet routinely implemented for this specific patient population.

A diagnostic high field MRI during radiotherapy, e.g. week 3 is optional.

Follow-up is also according to standard of care (except for patient reported outcome measure using QLQ-C30 and QLQ-PR25 and a diagnostic MRI at 9 months after SBRT (optional), and 12 months in the case of an image non-complete response at 9 months (optional).

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Interventional

Enrollment (Estimated)

54

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Baden-Würtemberg
      • Heidelberg, Baden-Würtemberg, Germany, 69120
        • University Clinic Heidelberg
        • Contact:
          • Jürgen Debus
    • Canton of Zurich
      • Zurich, Canton of Zurich, Switzerland, 8091
        • University Hospital Zurich
        • Contact:
          • Matthias Guckenberger
        • Contact:
          • Tiuri Kroese

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion criteria include:

  • Regionally metastatic prostate cancer (cN1, cT1-cT3, Gleason 6-10, any PSA) according to NCCN guidelines consisting of ≤ 5 regional lymph node metastases
  • Good to moderate performance status (WHO 0-2)
  • Written informed consent.
  • A PSMA PET and multiparametric MRI is mandatory according to staging guidelines.
  • Age ≥ 18 years

Exclusion criteria include:

  • >5 regional lymph nodes

  • Patients with cT4 disease (tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall)

  • Previous radiotherapy to the pelvis or prostate

  • Previous radical prostatectomy

  • Large body size that would not fit into the MRI-simulator bore

  • Presence of distant metastases (i.e. cM1)

    • Non-regional lymph nodes (M1a):
    • Bone metastases (M1b)
    • Other sites (M1c)
  • Contraindications to CT or MR-adaptive SBRT (e.g., pacemakers, severe claustrophobia).

  • Severe comorbidities that may interfere with treatment or follow-up (e.g. inflammatory bowel disease).

  • Significant concomitant diseases (e.g. hepatic dysfunction, cardiovascular disease, etc.).

  • Inability to follow procedures or insufficient knowledge of project language, inability to give consent.

  • Participation in a clinical trial which might influence the results of this project.

  • Enrolment of the investigator, his/her family members, employees and other dependent persons.

  • Severe genitourinary or gastrointestinal symptoms (e.g. recent urinary retention or diarrhea ≥ grade 3 or obstipation to CTCAE v.6.0).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Single Group Study

Assessment of weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy.

Patients will be treated with weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy. A simultaneous integrated boost (SIB) of involved lymph nodes will be performed. In the case of up to 2 dominant intraprostatic lesion (DIL) a SIB of the DIL can be performed (optional). Importantly, coverage of these DIL volumes must be compromised as needed to respect OAR constraints.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility- a successful delivery of CT or MR-informed SBRT per fraction
Time Frame: from Day 1 of treatment up to 7 weeks until end of treatment

Feasibility will be assessed by recording whether each fraction of stereotactic body radiation therapy (SBRT), guided by computed tomography (CT) or magnetic resonance (MR) imaging, is successfully delivered according to the planned treatment parameters. Successful delivery is defined as completion of the planned fraction without protocol deviations or technical interruptions. Data will be summarized as the proportion of fractions successfully delivered per patient and overall. Every treatment fraction having passed the point of entry into the adaptive workflow will be analyzed for this endpoint.

from Day 1 of treatment up to 7 weeks until end of treatment
Safety - Adverse events
Time Frame: ≥ 3 months to within 1 year after completion of SBRT

The presence of genitourinary or gastrointestinal toxicity of grade ≥ 3 within 1 year after completion of radiotherapy (according to CTCAE v5.0). Treatment-related discontinuation. and Subgroup analyses will be performed for patients with and without regional lymph node metastases (i.e., cN0 versus cN1).

≥ 3 months to within 1 year after completion of SBRT

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Biochemical progression-free survival
Time Frame: from Day 1 up to 5 years after treatment

This will be determined from the start of therapy until the occurrence of PSA recurrence according to the Phoenix criteria i.e. post- therapeutic PSA nadir + 2 ng/ml

from Day 1 up to 5 years after treatment
Castration-resistant free survival
Time Frame: from Day 1 up to 5 years after treatment

Castration-resistant free survival defined as cancer progression despite low (castrate) levels of testosterone (<50 ng/dL). Cancer progression is defined as:

  • Biochemical progression: ≥2 consecutive PSA rises (at least 1 week apart)
  • Radiologic progression: appearance of new lesions on imaging
from Day 1 up to 5 years after treatment
Patients Quality of Life EQ-5D-5L from the European Organisation for Research and Treatment of Cancer
Time Frame: from Day 1 up to end of study until 5 years

Quality-of-life will be measured using the EQ-5D-5L questionnaire during and after treatment

All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.

from Day 1 up to end of study until 5 years
Patients Quality of Life QLQ-C30 from the European Organisation for Research and Treatment of Cancer
Time Frame: From Day 1 up to end of study (up to 5 years)

Quality of life will be measured using the EORTC QLQ-C30 questionnaire. This instrument includes functional scales, symptom scales, and a global health status/quality-of-life scale. All scores are linearly transformed to a 1-4 scale. For functional scales and global health status, higher scores indicate better functioning or quality of life, whereas for symptom scales/items, higher scores indicate greater symptom burden.

From Day 1 up to end of study (up to 5 years)
Adverse events
Time Frame: from Day 1 until 5 years or end of Study

Genitourinary and Gastrointestinal toxicity measured with Common Terminology Criteria for Adverse Events (CTCAE)

from Day 1 until 5 years or end of Study
Patients overall survival
Time Frame: from Day 1 until Progression or death whichever comes first until 5 years

defined from the start of therapy until death or censoring

from Day 1 until Progression or death whichever comes first until 5 years
Patient overall treatment - Patient treatment workflow duration (time from MRI scan start to completion of treatment)
Time Frame: from Day 1 start of therapy, weekly until end of treatment up to 7 weeks

Patient will be asked from the start and end of MRI scan to start and end of treatment respectively, and for all steps from simulation to treatment delivery individually

from Day 1 start of therapy, weekly until end of treatment up to 7 weeks
Other Toxicities
Time Frame: Day 1 of Treatment for up to 5 years or until death whichever comes first

Treatment-related toxicities other than the primary toxicity outcomes will be assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE). Other Toxicities will be evaluated during SBRT treatment and throughout follow-up for up to 5 years after completion of treatment or until patient death, whichever occurs first. The type, frequency, and severity (grade) of adverse events will be recorded according to CTCAE v5.0 criteria.

Day 1 of Treatment for up to 5 years or until death whichever comes first
Dosimetry difference
Time Frame: from Day 1 of treatment start until end of treatment up to 7 Weeks

Dosimetry difference of the online adaptive plan compared to the original plan recalculated on the imaging of the day. Dosimetry difference is defined as difference in coverage of the planning target volume (PTV) or of one of the organs at risk e.g. bowel or rectum

from Day 1 of treatment start until end of treatment up to 7 Weeks
Anatomy changes assessed on magnetic resonance imaging (MRI)
Time Frame: from Day 1 of treatment up to 7 weeks

Anatomical changes will be evaluated using serial magnetic resonance imaging (MRI) acquired during treatment and follow-up. Changes in relevant anatomical structures (e.g., target volume and surrounding organs at risk) will be assessed by comparing images obtained at baseline and subsequent imaging time points. Observed anatomical variations will be documented and summarized descriptively.

from Day 1 of treatment up to 7 weeks
Comparison of Patient treated and not treated
Time Frame: from Day 1 until 5 Years of study or death

Comparison of number of patients not treated at all/not treated with all planned fractions in the CT or MR-informed workflow compared to those intended to be treated and categorization of patterns of failure within the CT or MR-informed workflow.

from Day 1 until 5 Years of study or death
Patient compliance
Time Frame: from Day 1 until 5 Years / end of Study

Patient compliance will be measured by tracking a scheduled treatment sessions and adherence to the prescribed treatment protocol, including completion of all required procedures and instructions. Data will be collected throughout the treatment period and summarized as the proportion of scheduled sessions attended and procedures completed, as well as reasons for any missed sessions or deviations from the protocol.

from Day 1 until 5 Years / end of Study
Patient well being and comfort
Time Frame: from Day 1 of treatment to weekly up to 7 weeks

Patients will be asked to report their comfort during and after simulation assess with a 0 to 10 numerical rating scales, with 0 representing complete absence of clinical confidence to 10 representing extreme clinical confidence

from Day 1 of treatment to weekly up to 7 weeks
Physician decision certainty
Time Frame: from Day1 of treatment to weekly up to 7 weeks

clinicians will be asked to report their clinical confidence with a 0 to 10 NRS, with 0 representing complete absence of clinical confidence to 10 representing extreme clinical confidence

from Day1 of treatment to weekly up to 7 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Matthias Guckenberger, University of Zurich
  • Study Chair: Matthias Guckenberger, Universitätsspital Zürich
  • Principal Investigator: Tiuri Kroese, University of Zurich

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

July 1, 2029

Study Completion (Estimated)

January 1, 2033

Study Registration Dates

First Submitted

March 11, 2026

First Submitted That Met QC Criteria

May 12, 2026

First Posted (Actual)

May 15, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe